

# International Immunopharmacology

---

## Aims and Scope

*International Immunopharmacology* is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome. The subject material appropriate for submission includes:

- Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders.
- Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state.
- Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immuno-modulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses.
- Pharmacological compounds, microbial products and toxicological agents that effect the lymphoid system, and their mechanisms of action.
- Agents that activate genes or modify transcription and translation within the immune response.
- Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active.
- Production, function and regulation of cytokines and their receptors.
- Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.
- Studies on the nature and function of drug and hormone receptors on lymphocytes and other cells in the immune system.
- Studies of cell-derived or humoral factors that modify the immune system causing cytotoxicity, inducing antibody production and mediating inflammatory responses.
- The development of immunologically based assays and their application to disease, including assays for drugs, hormones, cyclic nucleotides, tumor antigens, etc.

## Editor in Chief

**J.E. Talmadge**, Dept. of Pathology and Microbiology, University of Nebraska Medical Center, 987660 Nebraska Med. Ctr. Omaha NE 68198-7660, USA. Tel.: +1 402 559 5639; fax: +1 402 559 4990; e-mail: jtalmadg@immpharm.com

## Associate Editors

**F. Abe**, International Immunopharmacology, Associate Editor, shimoda-cho 4-1-8-305, Kouhoku-ku, Yokohama 223-0064, Japan; e-mail: abegen@wa3.so-net.ne.jp

**K. Alun Brown**, New Guy's House, 3rd Floor, Dept. of Immunobiology, Guy's and St. Thomas's, Lambeth Palace Road, London SE1 7EH, UK. Tel: +44 207 955 4561; fax: +44 207 955 1637; e-mail: alun.brown@kcl.ac.uk

**W.R. Green**, Dept. of Microbiology, Borwell Bldg., Dartmouth Med. School, 1 Medical Centre Drive, Lebanon, NH 03756, USA. Tel: +1 603 650 8607; fax: +1 603 650 6223; e-mail: William.R.Green@dartmouth.edu

**H. Kobayashi**, Professor Emeritus, Graduate School of Pharmaceutical Sciences, Chiba University; e-mail: hiroshi.k@mx6.ttcn.ne.jp

**F. Marceau**, Centre de recherche en rhumatologie et immunologie, Room T1-49, CHU de Québec, 2705 Laurier Blvd. Québec QC, Canada G1V 4G2 Tel.: 418 525 4444 ext. 46155; Fax: 418 654 2765; e-mail: francois.marceau@crchul.ulaval.ca

**P.T. Peachell**, Section of Molecular Pharmacology, Royal Hallamshire Hosp. Floor L, Royal Hallamshire Hospital, Sheffield, Royal Hallamshire Hospital Glossop Road, Sheffield, S10 2JF, UK.; Tel.: +44 114 271 2063; Fax: +44 114 272 0275; Email: p.t.peachell@shef.ac.uk

**J.M. Wang**, Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute at Frederick National Institutes of Health, Building 560, Room 31-76, Frederick, Maryland 21702. Tel.: +13018466979; fax: +13018467042; e-mail: wangji@mail.nih.gov

## Founding Co-Editor-in-Chief

**T.E. Hugli**, San Diego, CA, USA

## Editorial Board

**J. Actor**, Houston, TX, USA  
**S.A. Ahmed**, Blacksburg, VA, USA  
**S. Basu**, Columbus, OH, USA  
**K. Bhoola**, Perth, Western Australia  
**X. Cao**, Shanghai, China  
**D. Capone**, Napoli, Italy  
**K. Chen**, Frederick, MD, USA  
**M. Ennis**, Belfast, Ireland  
**L. Erickson**, Charlottesville, VA, USA  
**R.L. Fairchild**, Cleveland, OH, USA  
**H. Fujii**, Tokyo, Japan  
**R. Gogal**, Athens, GA, USA

**A.L. Goldstein**, Washington DC, USA  
**N. Hirasawa**, Miyagi, Japan  
**N. Inagaki**, Gifu, Japan  
**P. Iribarren**, Cordoba, Argentina  
**N.E. Kaminski**, East Lansing, MI, USA  
**M. Kawada**, Shizuoka, Japan  
**Y. Kawakami**, Tokyo, Japan  
**M. Lang**, Oklahoma City, OK, USA  
**X.-K. Li**, Tokyo, Japan  
**F. Marceau**, Québec, Canada  
**P.J. Nicholls**, Cardiff, UK  
**N. Ohno**, Tokyo, Japan

**P.T. Peachell**, Sheffield, UK  
**L. Pelus**, Indianapolis, IN, USA  
**T.M. Petro**, Lincoln, NE, USA  
**M. Pouliot**, QC, Canada  
**K. Resch**, Hannover, Germany  
**S. Sozzani**, Brescia, Italy  
**L. Thomas**, Chicago, IL, USA  
**V.K. Tuohy**, Cleveland, OH, USA  
**L. Varesio**, Genova Quarto, Italy  
**C. Wu**, Shenyang, China  
**T. Yoshida**, Tokyo, Japan  
**X. Zhang**, Chicago, IL, USA  
**X. Zhang**, Chongqing, China

---

The cover illustration is reproduced with permission of the providers, R. Bryan Sutton (University of Texas Medical Branch at Galveston) and Sunil Chada (Introgen Therapeutics in Houston), and shows the glycosylation sites on the IL-24 molecule.